Human Technopole

Human Technopole has presented 102 research projects that were the first to benefit from the cutting-edge equipment of the National Facilities — the advanced technologies that the Institute makes available to external researchers from across Italy. The majority of studies focus on cancer and neurodegenerative diseases, accounting for 50% of the selected projects. The announcement was made this morning in Milan during “Open HT – The Open Day on Life Sciences”, an event designed to showcase Human Technopole’s achievements and outline future goals.

Human Technopole is offering up to 10 fully funded PhD scholarships through the SEMM PhD Program in Systems Medicine. These scholarships are open to talented and motivated graduates—both from Italy and abroad – interested in pursuing doctoral research.

Using advanced stem cell models, Human Technopole researchers show how mutations in the YY1 gene cause widespread dysregulation of genes crucial for brain development in multiple cell types, leading to structural abnormalities and impaired neuronal function. The results of the research are published in the Nature Portfolio journal Molecular Psychiatry.

Human Technopole is proud to announce the launch of its new Gender Equality Plan (GEP) for 2025-2027, a strategic initiative designed to further integrate gender equality across all aspects of the Institute, building upon the successful outcomes of the previous GEP (2022-2024). HT has also achieved the UNI/PdR 125:2022 certification, which recognizes organizations that promote gender equality and foster inclusive workplaces.

Human Technopole is offering 2 fully funded 4-year PhD fellowships to young scientists from the national and international community who wish to undertake a doctoral degree on a project focused on Computational Biology.

Meet Alice Giustacchini, Research Group Leader in Population and Medical Genomics. Her project, titled “Tailoring Precision Immunotherapy to Paediatric Acute Myeloid Leukaemia,” aims to study the cellular and molecular dynamics of CAR-T cell therapy in blood cancers.